Sandoz Tested Erelzi’s Suffix On Multiple Fronts

Evaluations of potential nonproprietary name suffixes for the US biosimilar to Amgen’s Enbrel included checks on Internet search engines and databases of abbreviations and proprietary names, as well as safety, trademark and phonetic analyses.

Sandoz Inc.’s defense of its preferred nonproprietary name suffixes for the biosimilar Erelzi (etanercept-szzs) included a list of analyses conducted to ensure the distinguishable modifiers did not run afoul of FDA guidelines.

As was the case with Amgen Inc.’s biosimilar Amjevita (adalimumab-atto), Sandoz ran into objections from FDA over its proposed...

More from Drug Review Profiles

More from Product Reviews

Gilead’s Lenacapavir Up For EMA Verdict Amid Packed CHMP Meeting Agenda

 
• By 

The European Medicines Agency’s, human medicines committee, the CHMP, is this week poised to issue opinions on potential marketing approvals for 17 products.

Gene Therapy Elevidys Among Six Orphan Drugs Awaiting EU Marketing Verdict

 
• By 

The European Medicines Agency is expected to decide whether to recommend EU-wide marketing authorization for six orphan-designated medicines that are all already approved in the US.

Business Background Of New CDER Director George Tidmarsh

 

George Tidmarsh has extensive experience in the biopharmaceutical industry and led several drugs to FDA approval.